Department of Hematology and Oncology, Johann Wolfgang Goethe University of Frankfurt, Frankfurt am Main, Germany.
University Center for Infectious Diseases, University Hospital Frankfurt, Frankfurt am Main, Germany.
PLoS One. 2018 Jul 19;13(7):e0201169. doi: 10.1371/journal.pone.0201169. eCollection 2018.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers potential cure to acute myeloid leukemia (AML) patients. However, infections with commensal bacteria are an important cause for non-relapse mortality (NRM). We have previously described the impact of multidrug-resistant organism (MDRO) colonization on the survival of allo-HSCT patients. In the aforementioned publication, according to consensus, we there did not consider the opportunistic gram-negative bacterium Stenotrophomonas maltophilia (S. maltophilia) to be an MDRO. Since rate of S. maltophilia colonization is increasing, and it is not known whether this poses a risk for allo-HSCT patients, we here analyzed here its effect on the previously described and now extended patient cohort. We report on 291 AML patients undergoing allo-HSCT. Twenty of 291 patients (6.9%) were colonized with S. maltophilia. Colonized patients did not differ from non-colonized patients with respect to their age, remission status before allo-HSCT, donor type and HSCT-comorbidity index. S. maltophilia colonized patients had a worse overall survival (OS) from 6 months up to 60 months (85% vs. 88.1% and 24.7% vs. 59.7%; p = 0.007) due to a higher NRM after allo-HSCT (6 months: 15% vs. 4.8% and 60 months: 40.1% vs. 16.2% p = 0.003). The main cause of mortality in colonized patients was infection (46.2% of all deaths) and in non-colonized patients relapse (58.8% of all deaths). 5/20 colonized patients developed an invasive infection with S. maltophilia. The worse OS after allo-HSCT due to higher infection related mortality might implicate the screening of allo-HSCT patients for S. maltophilia and a closer observation of colonized patients as outpatients.
异基因造血干细胞移植(allo-HSCT)为急性髓系白血病(AML)患者提供了潜在的治愈方法。然而,共生细菌感染是导致非复发死亡率(NRM)的一个重要原因。我们之前已经描述了多药耐药菌(MDRO)定植对 allo-HSCT 患者生存的影响。在上述出版物中,根据共识,我们没有将机会性革兰氏阴性菌嗜麦芽窄食单胞菌(S. maltophilia)视为 MDRO。由于 S. maltophilia 定植率正在增加,并且尚不清楚这是否对 allo-HSCT 患者构成风险,因此我们在此分析了其对之前描述并现在扩展的患者队列的影响。我们报告了 291 例接受 allo-HSCT 的 AML 患者。291 例患者中有 20 例(6.9%)定植了 S. maltophilia。定植患者与非定植患者在年龄、allo-HSCT 前缓解状态、供者类型和 HSCT 合并症指数方面没有差异。由于 allo-HSCT 后 NRM 较高,S. maltophilia 定植患者的总生存(OS)从 6 个月到 60 个月均较差(85%比 88.1%和 24.7%比 59.7%;p=0.007)(6 个月:15%比 4.8%和 60 个月:40.1%比 16.2%,p=0.003)。定植患者死亡的主要原因是感染(所有死亡的 46.2%),而非定植患者死亡的主要原因是复发(所有死亡的 58.8%)。20 例定植患者中有 5 例发生了侵袭性 S. maltophilia 感染。由于感染相关死亡率较高,allo-HSCT 后 OS 较差可能意味着需要对 allo-HSCT 患者进行 S. maltophilia 筛查,并对定植患者作为门诊患者进行更密切的观察。